Vice President, Process Development
Vir Biotechnology
Summary
Vir Biotechnology is seeking a Vice President, Process Development to lead our global Drug Substance Process Development and Manufacturing Sciences & Technology (MSAT) organization. Reporting to the Chief Technology Officer, this leader will oversee process development, technology transfer, manufacturing support, and lifecycle management across Vir Bio's portfolio.
Job description
The Opportunity
Vir Biotechnology is seeking a Vice President, Process Development to lead our global Drug Substance Process Development and Manufacturing Sciences & Technology (MSAT) organization. Reporting to the Chief Technology Officer, this leader will oversee process development, technology transfer, manufacturing support, and lifecycle management across Vir Bio's portfolio.
You will lead a high-performing team and define and execute drug substance strategies for monoclonal antibodies, T-cell engagers, and other large molecule biologics within a highly outsourced manufacturing environment. As a key CMC leader, you will drive cross-functional alignment, solve complex development and manufacturing challenges, and partner closely with internal teams and external manufacturers to advance programs.
This role is based in our San Francisco headquarters, with an expectation of being onsite at least three days per week.
What You'll Do
- Lead the global Drug Substance Process Development and MSAT organization, fostering scientific excellence, accountability, and collaboration
- Define and execute drug substance strategies across the product lifecycle, including process development, scale-up, characterization, validation, technology transfer, and lifecycle management
- Set the long-term Drug Substance development strategy to create innovative solutions for developing efficient, robust and cost-effective processes for Mabs and masked T-cell engagers to support the current portfolio and future pipeline
- Oversee manufacturing support and process performance across our external manufacturing network
- Work closely with other TechOps and Quality functions to participate in comprehensive CMC development of Vir Bio pipeline molecules
- Serve as a key CMC leader across development programs, driving alignment and execution against scientific, technical, and business objectives
- Lead technology transfers to CDMOs, proactively managing technical and operational risk
- Build strong partnerships with external development and manufacturing organizations
- Represent Vir in interactions with FDA, EMA, and other global health authorities, including regulatory submissions, inspections, and agency responses
- Partner with executive leadership on portfolio planning, organizational design, resource prioritization, and investment decisions
- Develop scientific leaders and organizational capabilities to support pipeline growth
- Drive operational excellence, continuous improvement, and scalable development practices across the organization
Who You Are and What You Bring
- PhD in Chemical Engineering, Biochemical Engineering, Biotechnology, Biology, or a related scientific discipline preferred
- 15+ years of biotechnology or pharmaceutical industry experience, including significant leadership experience within biologics process development
- Deep expertise in Cell Line Development and Upstream Process Development preferred, with broad experience across drug substance process development for monoclonal antibodies, T-cell engagers, and other large molecule biologics
- Demonstrated success advancing biologics programs from early development through commercialization
- Extensive experience across process scale-up, characterization, validation, technology transfer, and manufacturing support
- Strong experience leading development and manufacturing activities within a highly outsourced CDMO environment
- Strong understanding of CMC development, regulatory submissions, and global health authority interactions
- Proven ability to build and develop high-performing teams and scientific leaders
Requirements
- PhD in Chemical Engineering, Biochemical Engineering, Biotechnology, Biology, or a related scientific discipline preferred
- 15+ years of biotechnology or pharmaceutical industry experience, including significant leadership experience within biologics process development
- Deep expertise in Cell Line Development and Upstream Process Development preferred
- Broad experience across drug substance process development for monoclonal antibodies, T-cell engagers, and other large molecule biologics
- Demonstrated success advancing biologics programs from early development through commercialization
- Extensive experience across process scale-up, characterization, validation, technology transfer, and manufacturing support
- Strong experience leading development and manufacturing activities within a highly outsourced CDMO environment
- Strong understanding of CMC development, regulatory submissions, and global health authority interactions
- Proven ability to build and develop high-performing teams and scientific leaders
- Must currently be authorized to work for any employer in the U.S.
Benefits
- Health & Welfare Benefits
- Non-Accrual PTO
- Company Holiday Shutdown
- Commuter Benefits
- 401(k) Match
- Daily Office Lunch
- Bonus
- Equity
Company overview
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, that leverages the immense potential of the immune system to address critical unmet medical needs. Founded in 2016, the company focuses on discovering and developing transformative medicines for serious infectious diseases and cancer. Vir Biotechnology's innovative approach combines deep immunology expertise with cutting-edge technology platforms, including a next-generation antibody platform and the PRO-XTEN® protease-releasable masking technology. The company's clinical-stage portfolio includes promising programs for chronic hepatitis delta and chronic hepatitis B infections, as well as multiple dual-masked T-cell engagers targeting various solid tumor indications. With operations in both the United States and Europe, Vir Biotechnology maintains a strong commitment to advancing novel therapies that can significantly improve patient outcomes. The company has demonstrated its capabilities through groundbreaking work in immunology, including contributions to COVID-19 and Ebola treatments, and continues to work with urgency to deliver potentially life-changing medicines to patients waiting for better treatment options.